PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-32.93%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
-386.54%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
2.68%
Operating expenses growth 0-5% reflects moderate increase. Benjamin Graham would check revenue alignment.
2.68%
Total costs growth 0-3% reflects moderate increase. Benjamin Graham would check revenue alignment.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-2.70%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-10.91%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-2.79%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.79%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
1.20%
EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
2.99%
Diluted EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
3.80%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
6.10%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.